HIV cure trial mergers: Spotlighting the epigenetics of latency reversal.
作者信息
Denton Paul W
机构信息
Department of Biology, University of Nebraska Omaha, Omaha, NE, USA.
出版信息
EBioMedicine. 2022 May;79:104012. doi: 10.1016/j.ebiom.2022.104012. Epub 2022 Apr 19.
Abstract
摘要
相似文献
1
HIV cure trial mergers: Spotlighting the epigenetics of latency reversal.艾滋病治愈试验合并：聚焦潜伏期逆转的表观遗传学
EBioMedicine. 2022 May;79:104012. doi: 10.1016/j.ebiom.2022.104012. Epub 2022 Apr 19.
2
Deep latency: A new insight into a functional HIV cure.深度潜伏：功能性 HIV 治愈的新见解。
EBioMedicine. 2019 Jul;45:624-629. doi: 10.1016/j.ebiom.2019.06.020. Epub 2019 Jun 18.
3
The sounds of silencing: dynamic epigenetic control of HIV latency.沉默的声音：HIV 潜伏期的动态表观遗传控制。
Curr Opin HIV AIDS. 2024 May 1;19(3):102-109. doi: 10.1097/COH.0000000000000850. Epub 2024 Mar 12.
4
Tackling latency as a barrier to an HIV cure: what next?
Lancet HIV. 2015 Dec;2(12):e504-5. doi: 10.1016/S2352-3018(15)00230-1. Epub 2015 Nov 17.
5
Naf1 Regulates HIV-1 Latency by Suppressing Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells.Naf1通过抑制原代CD4 + T细胞中病毒启动子驱动的基因表达来调节HIV-1潜伏。
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01830-16. Print 2017 Jan 1.
6
Regulation of human immunodeficiency virus-1 latency and its reactivation.人类免疫缺陷病毒1型潜伏状态的调控及其激活
Bull Mem Acad R Med Belg. 2008;163(6):355-64; discussion 364-5.
7
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.马拉维若与潜伏 HIV-1 再激活有关，通过抑制性抗逆转录病毒治疗的 HIV 感染者静息 CD4 T 细胞中 NF-κB 的激活。
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01931-17. Print 2018 May 1.
8
A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency.双色单倍体遗传筛选鉴定新型 HIV-1 潜伏期相关宿主因子。
mBio. 2021 Dec 21;12(6):e0298021. doi: 10.1128/mBio.02980-21. Epub 2021 Dec 7.
9
PIWIL4 Maintains HIV-1 Latency by Enforcing Epigenetically Suppressive Modifications on the 5' Long Terminal Repeat.PIWIL4 通过对 5' 长末端重复序列施加表观遗传抑制修饰来维持 HIV-1 潜伏期。
J Virol. 2020 May 4;94(10). doi: 10.1128/JVI.01923-19.
10
A broad drug arsenal to attack a strenuous latent HIV reservoir.用广泛的药物武器来攻击顽固的潜伏 HIV 储库。
Curr Opin Virol. 2019 Oct;38:37-53. doi: 10.1016/j.coviro.2019.06.001. Epub 2019 Jul 16.
引用本文的文献
1
Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials.保守型多表位疫苗构建体：临床试验中的一种有效的 HIV-1 治疗性疫苗。
Braz J Infect Dis. 2023 May-Jun;27(3):102774. doi: 10.1016/j.bjid.2023.102774. Epub 2023 May 5.
本文引用的文献
1
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.在“踢杀”治疗性疫苗 BCN02 临床试验中，表观遗传景观与抗逆转录病毒治疗中断 (ATI) 结果相关。
EBioMedicine. 2022 Apr;78:103956. doi: 10.1016/j.ebiom.2022.103956. Epub 2022 Mar 21.
2
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.艾滋病治愈研究重点：2021年国际艾滋病学会全球科学战略
Nat Med. 2021 Dec;27(12):2085-2098. doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 1.
3
Transcriptional behavior of the HIV-1 promoter in context of the BACH2 prominent proviral integration gene.HIV-1 启动子在 BACH2 显著前病毒整合基因背景下的转录行为。
Virus Res. 2021 Feb;293:198260. doi: 10.1016/j.virusres.2020.198260. Epub 2020 Dec 11.
4
The case for an HIV cure and how to get there.实现 HIV 治愈的理由与路径
Lancet HIV. 2021 Jan;8(1):e51-e58. doi: 10.1016/S2352-3018(20)30232-0. Epub 2020 Nov 30.
5
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).HIVconsv 疫苗联合罗米地辛治疗早期 HIV-1 感染者：安全性、免疫原性和对病毒储存库的影响（BCN02 研究）。
Front Immunol. 2020 May 6;11:823. doi: 10.3389/fimmu.2020.00823. eCollection 2020.
6
Curing HIV: Seeking to Target and Clear Persistent Infection.治愈 HIV：寻求靶向和清除持续性感染。
Cell. 2020 Apr 2;181(1):189-206. doi: 10.1016/j.cell.2020.03.005. Epub 2020 Mar 26.
7
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).治疗性疫苗使早期接受治疗的个体的T细胞反应重新聚焦于HIV-1的保守区域（BCN 01研究）。
EClinicalMedicine. 2019 Jun 5;11:65-80. doi: 10.1016/j.eclinm.2019.05.009. eCollection 2019 May-Jun.
8
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.一项在感染早期开始接受抗逆转录病毒治疗的 HIV 感染者中进行的治疗性疫苗接种的随机对照安全性/疗效试验。
Sci Transl Med. 2017 Dec 6;9(419). doi: 10.1126/scitranslmed.aan8848.
9
PKCθ and HIV-1 Transcriptional Regulator Tat Co-exist at the LTR Promoter in CD4(+) T Cells.蛋白激酶Cθ（PKCθ）与HIV-1转录调节因子反式激活因子（Tat）在CD4(+) T细胞的长末端重复序列（LTR）启动子处共存。
Front Immunol. 2016 Feb 29;7:69. doi: 10.3389/fimmu.2016.00069. eCollection 2016.
10
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.缩肽类药物罗米地辛可在体内逆转HIV-1潜伏感染。
PLoS Pathog. 2015 Sep 17;11(9):e1005142. doi: 10.1371/journal.ppat.1005142. eCollection 2015 Sep.
Zotero 插件